

Agenda: To review and evaluate grant applications.

Place: Video Assisted Meeting.

Contact Person: Leonid V. Tsap, Ph.D., Scientific Review Officer, Extramural Programs, National Library of Medicine, NIH, 6705 Rockledge Drive, Suite 500, Bethesda, MD 20892-7968, 301-827-7077, tsapl@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program No. 93.879, Medical Library Assistance, National Institutes of Health, HHS)

Dated: November 2, 2020.

Ronald J. Livingston, Jr.,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020-24669 Filed 11-5-20; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Aging; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant

applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Aging Special Emphasis Panel; Clinical trials for COVID 19 management in older individuals.

Date: December 11, 2020.

Time: 10:00 a.m. to 1:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Maurizio Grimaldi, MD, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Aging, National Institutes of Health, 7201 Wisconsin Avenue, Gateway Building, Suite 2W200, Bethesda, MD 20892, (301) 496-9374, grimaldim2@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: November 2, 2020.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020-24615 Filed 11-5-20; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive Patent License: Treatment of Hermansky-Pudlak Syndrome and Idiopathic Pulmonary Fibrosis

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Heart, Lung and Blood Institute (NHLBI) and the National Human Genome Research Institute (NHGRI), both of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an exclusive patent license to Inversago Pharma Inc., located in Montreal, Quebec, Canada, to practice the inventions embodied in the patent applications listed in the **SUPPLEMENTARY INFORMATION** section of this notice.

DATES: Only written comments and/or applications for a license which are received by the National Human Genome Research Institute's Technology Transfer Office on or before November 23, 2020 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated exclusive patent license should be directed to: Anna Solowiej, Ph.D., J.D., Senior Licensing and Patenting Manager, NHGRI Technology Transfer Office; Telephone (301) 435-7791; Email: anna.solowiej@nih.gov.

SUPPLEMENTARY INFORMATION: The following and all continuing U.S. and foreign patents/patent applications thereof are the intellectual properties to be licensed under the prospective agreement to Inversago Pharma Inc.:

| NIH ref No. | Patent No. or application No. | Issue date | Filing date | Title |
|---------------------|-------------------------------|---------------------------|-------------------|---|
| E-282-2012-0-US-01 | 61/725,949 | | November 13, 2012 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-PCT-02 | PCT/US2013/069686 | | November 12, 2013 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-US-03 | 9,765,031 | September 19, 2017 | November 12, 2013 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-CA-04 | 2889697 | | April 27, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-EP-05 | 13802153.0 | TBD | June 01, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-CH-12 | 13802153.0 | TBD | November 12, 2013 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-DE-13 | 13802153.0 | TBD | November 12, 2013 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-FR-14 | 13802153.0 | TBD | November 12, 2013 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-GB-15 | 13802153.0 | TBD | November 12, 2013 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-IE-16 | 13802153.0 | TBD | November 12, 2013 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-IN-06 | 3733/DELNP/2015 | | May 1, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-JP-07 | 6272626 | January 12, 2018 | May 11, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-CN-08 | ZL201380069389.9 | August 20, 2019 | July 3, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-US-09 | 10,683,270 | June 16, 2020 | August 10, 2017 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-US-10 | 15/674,333 | TBD (application allowed) | August 10, 2017 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-US-11 | 16/870,093 | | May 8, 2020 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-1-US-01 | 62/171,179 | | June 4, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-1-PCT-02 | PCT/US2016/035291 | | June 1, 2016 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-1-EP-05 | 16/28547.7 | | June 1, 2016 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-1-US-08 | 15/579,123 | | December 1, 2017 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-1-US-09 | 16/438,850 | | June 12, 2019 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-2-US-01 | 15/061,829 | | March 4, 2016 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-2-PCT-02 | PCT/US2017/020250 | | March 1, 2017 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-2-CN-03 | 2017800118698 | | March 1, 2017 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-2-EP-04 | 17711443.6 | | March 1, 2017 | Cannabinoid Receptor Mediating Compounds. |
| E-140-2014-0-US-01 | 61/991,333 | | May 9, 2014 | Cannabinoid Receptor Mediating Compounds. |
| E-140-2014-0-PCT-02 | PCT/US2015/029946 | | May 8, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-140-2014-0-AU-03 | 2015255765 | | November 7, 2016 | Cannabinoid Receptor Mediating Compounds. |
| E-140-2014-0-CA-04 | 2948349 | | May 8, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-140-2014-0-CN-05 | 201580028788.X | February 7, 2020 | May 8, 2015 | Cannabinoid Receptor Mediating Compounds. |

| NIH ref No. | Patent No. or application No. | Issue date | Filing date | Title |
|--------------------------|-------------------------------|--------------------------------|------------------------|---|
| E-140-2014-0-EP-06 | 15728668.3 | | May 8, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-140-2014-0-IN-07 | 201637038171 | | November 8, 2016 | Cannabinoid Receptor Mediating Compounds. |
| E-140-2014-0-JP-08 | 2017-511558 | TBD (application allowed) | May 8, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-140-2014-0-US-09 | 10,329,259 | June 25, 2019 | November 8, 2016 | Cannabinoid Receptor Mediating Compounds. |
| E-140-2014-0-HK-10 | 17105705.6 | | June 9, 2017 | Cannabinoid Receptor Mediating Compounds. |
| E-140-2014-0-AU-11 | 2019227889 | | May 8, 2015 | Cannabinoid Receptor Mediating Compounds. |

The patent rights in these inventions have been assigned to the Government of the United States of America.

The prospective exclusive patent license territory may be worldwide and a field of use limited to human therapeutics for Hermansky-Pudlak syndrome and idiopathic pulmonary fibrosis. The invention covered by the patents and patent applications pertaining to HHS Ref. No. E-282-2012 relates to cannabinoid receptor 1 (CB₁R) inverse agonists. CB₁R activation plays a key role in appetitive behavior, metabolism, and tissue fibrosis. Of importance as a therapeutic target here is that the receptor is expressed in both peripheral tissue as well as the central nervous system. The invention is a class of pyrazole compounds that act as CB₁ receptor inverse agonists and have been shown effective at reducing obesity and its associated metabolic consequences while having no experimentally discernable neuropsychotropic side effects that are considered adverse, unlike the earlier antagonists rimonabant. These CB₁R receptor compounds were developed with the goals of limiting their brain penetrance without losing their metabolic efficacy due to CB₁ inverse agonism, and having a primary metabolite directly targeting enzymes involved in inflammatory and fibrotic processes associated with metabolic and other disorders. The patents are both compositions of matter and methods of use.

The inventions covered by HHS Ref. E-140-2014-0 also pertain to pyrazole CB₁R receptor inverse agonists. In addition, some of these compounds also have a direct inhibitory effect on inducible nitric oxide synthase (iNOS), whereas another group of the compounds directly activates AMP kinase. There is evidence that the metabolic effects of endocannabinoids are mediated by CB₁ receptors in peripheral tissues. These dual-target compounds may be useful for treating metabolic disease and related conditions such as obesity and diabetes and their complications, including various forms of tissue fibrosis, without the dangerous side effects. This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive patent license will be royalty

bearing and may be granted unless within fifteen (15) days from the date of this published notice, NHGRI receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

Complete applications for a license in the prospective field of use that are timely filed in response to this notice will be treated as objections to the grant of the contemplated exclusive patent license.

Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the *Freedom of Information Act*, 5 U.S.C. 552.

Dated: November 2, 2020

Claire T. Driscoll,

*Director, Technology Transfer Office,
National Human Genome Research Institute.*

[FR Doc. 2020-24616 Filed 11-5-20; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; R13 Conferences and Scientific Meetings.

Date: December 11-14, 2020.

Time: 11:00 a.m. to 7:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20814 (Virtual Meeting).

Contact Person: Keith A Mintzer, Ph.D., Scientific Review Officer, Office of Review Branch/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 207-G, Bethesda, MD 20892-7924, (301) 827-7949, mintzerk@nhlbi.nih.gov.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; NHLBI Institutional Training Grants.

Date: December 15, 2020.

Time: 1:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Giuseppe Pintucci, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 205-H, Bethesda, MD 20892, (301) 827-7969, Pintuccig@nhlbi.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: November 2, 2020.

Ronald J. Livingston, Jr.,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020-24670 Filed 11-5-20; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning